MCID: MCR129
MIFTS: 62

Microvascular Complications of Diabetes 1

Categories: Genetic diseases, Eye diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 1

MalaCards integrated aliases for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 53 71 28 13
Proliferative Diabetic Retinopathy 12 71 51 14 69
Diabetic Nephropathy 71 69
Mvcd1 53 71
Microvascular Complications of Diabetes, Susceptibility to, 1 53
Nonproliferative Retinopathy, Diabetic, Susceptibility to 53
Proliferative Retinopathy, Diabetic, Susceptibility to 53
Nonproliferative Retinopathy, Diabetic 53
Non-Proliferative Diabetic Retinopathy 71
Nonproliferative Diabetic Retinopathy 69
Proliferative Retinopathy, Diabetic 53
Complications of Diabetes Mellitus 69
Diabetic End-Stage Renal Disease 71
Diabetes Complications 41
Diabetic Neuropathies 69
Diabetic Neuropathy 71
Pdr 12

Classifications:



Summaries for Microvascular Complications of Diabetes 1

UniProtKB/Swiss-Prot : 71 Microvascular complications of diabetes 1: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to microvascular complications of diabetes 5 and diabetic neuropathy, and has symptoms including sciatica and neuralgia. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, lung and brain, and related phenotypes are cardiovascular system and cellular

Wikipedia : 72 The complications of diabetes mellitus are far less common and less severe in people who have... more...

Description from OMIM: 603933

Related Diseases for Microvascular Complications of Diabetes 1

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 28.4 ANGPT2 FGF2 FLT1 ICAM1 IGF1 SERPINF1
2 diabetic neuropathy 12.5
3 pigmentary disorder, reticulate, with systemic manifestations, x-linked 11.5
4 microvascular complications of diabetes 3 11.5
5 background diabetic retinopathy 11.5
6 microvascular complications of diabetes 7 11.5
7 microvascular complications of diabetes 2 11.4
8 severe nonproliferative diabetic retinopathy 11.4
9 diabetic angiopathy 10.7
10 acidophil adenoma 10.5 IGF1 SST
11 pituitary infarct 10.5 IGF1 SST
12 wrinkles 10.5 HGF VEGFA
13 hormone producing pituitary cancer 10.4 IGF1 SST
14 pyogenic granuloma 10.4 ANGPT2 VEGFA
15 critical limb ischemia 10.4 ANGPT2 HGF VEGFA
16 carcinoid syndrome 10.4 IGF1 SST VEGFA
17 pituitary adenoma 1, multiple types 10.4 IGF1 SST
18 pituitary tumors 10.4 IGF1 SST VEGFA
19 angiodysplasia 10.4 FGF2 SST VEGFA
20 chronic myocardial ischemia 10.4 FGF2 HGF VEGFA
21 retinal vein occlusion 10.3 CCL2 SERPINF1 VEGFA
22 short bowel syndrome 10.3 HGF IGF1 SST
23 hemangioma 10.3 ANGPT2 FGF2 VEGFA
24 squamous cell carcinoma of the hypopharynx 10.3 MMP9 VEGFA
25 peripheral artery disease 10.3 CCL2 VCAM1 VEGFA
26 israeli tick typhus 10.3 CCL2 CXCL8
27 acquired metabolic disease 10.2 CCL2 IGF1 SST
28 toxicodendron dermatitis 10.2 CXCL8 ICAM1
29 vibratory urticaria 10.2 CXCL8 MMP9
30 male reproductive organ cancer 10.2 IGF1 MMP9 VEGFA
31 gastric ulcer 10.2 CXCL8 FGF2 HGF
32 lymphocytic vasculitis 10.2 ICAM1 VCAM1
33 reproductive organ cancer 10.2 IGF1 MMP9 VEGFA
34 clivus chordoma 10.2 CXCL12 FGF2
35 glomeruloid hemangioma 10.2 FLT1 VEGFA
36 keratitis, hereditary 10.2 FGF2 MMP9 VEGFA
37 acute transverse myelitis 10.2 CXCL8 MMP9
38 nodular goiter 10.2 HGF ICAM1 VEGFA
39 severe pre-eclampsia 10.2 MMP9 VCAM1 VEGFA
40 viral encephalitis 10.2 CCL2 CXCL8 VCAM1
41 sick building syndrome 10.2 MMP9 VEGFA
42 leukostasis 10.2 ICAM1 VCAM1 VEGFA
43 lipodermatosclerosis 10.1 ANGPT2 FLT1 VEGFA
44 renal fibrosis 10.1 CCL2 CTGF HGF
45 cortical thymoma 10.1 ICAM1 SST VCAM1
46 autosomal dominant polycystic kidney disease 10.1 CCL2 IGF1 VEGFA
47 placental insufficiency 10.1 ANGPT2 FLT1 VEGFA
48 arteriosclerosis obliterans 10.1 HGF ICAM1 VCAM1
49 preretinal fibrosis 10.1 TGFB2 VEGFA
50 vascular cancer 10.1 FGF2 FLT1 VEGFA

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 24)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Cataract
Diabetic Polyneuropathy Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Neurogenic Arthropathy Peripheral Vascular Disease
Rubeosis Iridis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:



Diseases related to Microvascular Complications of Diabetes 1

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

Clinical features from OMIM:

603933

UMLS symptoms related to Microvascular Complications of Diabetes 1:


sciatica, neuralgia

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

43 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 VCAM1 VEGFA ANGPT2 FLT1 CTGF CXCL12
2 cellular MP:0005384 10.29 VCAM1 VEGFA FGF2 ANGPT2 FLT1 CTGF
3 hematopoietic system MP:0005397 10.2 VCAM1 VEGFA ICAM1 FGF2 FLT1 HGF
4 growth/size/body region MP:0005378 10.18 TGFB2 VCAM1 VEGFA CTGF FLT1 HGF
5 immune system MP:0005387 10.18 VCAM1 VEGFA ANGPT2 FLT1 CCL2 CXCL12
6 mortality/aging MP:0010768 10.18 VCAM1 VEGFA ICAM1 FGF2 ANGPT2 FLT1
7 homeostasis/metabolism MP:0005376 10.17 VCAM1 VEGFA FGF2 ANGPT2 CTGF FLT1
8 digestive/alimentary MP:0005381 10.1 VEGFA ANGPT2 CTGF ICAM1 SERPINF1 SST
9 nervous system MP:0003631 9.96 VEGFA FGF2 FLT1 CXCL12 TGFB2 MMP9
10 muscle MP:0005369 9.92 VEGFA FGF2 FLT1 CXCL12 ICAM1 IGF1
11 reproductive system MP:0005389 9.81 VCAM1 VEGFA FGF2 FLT1 CXCL12 SERPINF1
12 skeleton MP:0005390 9.56 VEGFA FGF2 CTGF TGFB2 MMP9 SERPINF1
13 vision/eye MP:0005391 9.28 VEGFA ICAM1 FGF2 ANGPT2 FLT1 CTGF

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-02-2 5743
5
Dipivefrin Approved Phase 4 52365-63-6 3105
6
Empagliflozin Approved Phase 4 864070-44-0
7
Glimepiride Approved Phase 4 93479-97-1 3476
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
11
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
12
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
13
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
14
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
15 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Hematinics Phase 4
18 Micronutrients Phase 4
19 Trace Elements Phase 4
20 Vitamin B 12 Phase 4
21 Vitamin B 6 Phase 4
22 Vitamin B Complex Phase 4
23 Vitamins Phase 4
24 Antiemetics Phase 4,Phase 2,Not Applicable
25 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
27 Autonomic Agents Phase 4,Phase 2,Not Applicable
28 BB 1101 Phase 4,Phase 2,Not Applicable
29 Dexamethasone acetate Phase 4,Phase 2,Not Applicable 1177-87-3
30 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 HIV Protease Inhibitors Phase 4,Phase 2,Not Applicable
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
37
protease inhibitors Phase 4,Phase 2,Not Applicable
38 Hypoglycemic Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Arrhythmia Agents Phase 4,Phase 1
41
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
42 Folate Nutraceutical Phase 4
43 Vitamin B12 Nutraceutical Phase 4
44 Vitamin B9 Nutraceutical Phase 4
45
Triamcinolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 124-94-7 31307
46
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
47
Angiotensin II Approved, Investigational Phase 3 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
48
Fenofibrate Approved Phase 3 49562-28-9 3339
49
Simvastatin Approved Phase 3 79902-63-9 54454
50
Temazepam Approved, Investigational Phase 3,Phase 2 846-50-4 5391

Interventional clinical trials:

(show top 50) (show all 161)

# Name Status NCT ID Phase Drugs
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
2 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
3 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
4 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
5 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
6 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
7 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
8 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
9 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
10 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
11 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
12 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
13 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed NCT01594281 Phase 4 Ranibizumab
14 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
15 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
16 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
17 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
18 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Recruiting NCT03246152 Phase 4 Bevacizumab
19 Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema Recruiting NCT02985242 Phase 4 Empagliflozin;Glimepiride;Empagliflozin placebo;Glimepiride placebo
20 Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy Unknown status NCT00516464 Phase 3 Lucentis (ranibizumab)
21 Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy Unknown status NCT00347698 Phase 2, Phase 3 intravitreal injection of bevacizumab
22 Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) Unknown status NCT00370721 Phase 3 bevacizumab
23 Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study Completed NCT01813773 Phase 2, Phase 3 Intravitreal Aflibercept Injection (IAI)
24 Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N) Completed NCT00996437 Phase 2, Phase 3 Ranibizumab;Saline
25 HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population Completed NCT00600236 Phase 3
26 Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy Completed NCT00445003 Phase 3 Ranibizumab;Triamcinolone Acetonide
27 PRP vs Bevacizumab for PDR Treatment Completed NCT02705274 Phase 2, Phase 3 Bevacizumab
28 Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Completed NCT00443521 Phase 2, Phase 3 Triamcinolone Acetonide 4 mg intravitreal injection
29 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
30 Green Laser Photocoagulation Study in Proliferative Diabetic Retinopathy Completed NCT00355680 Phase 3
31 Bevacizumab and Long Acting Gas in Diabetic Vitrectomy Completed NCT00656435 Phase 3 Bevacizumab
32 Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy Completed NCT00131144 Phase 3 Octreotide Acetate in Microspheres 20 mg;Octreotide Acetate in Microspheres;Placebo
33 Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy Completed NCT00130845 Phase 3 Octreotide Acetate in Microspheres;Placebo
34 DIabetic Retinopathy Candesartan Trials Completed NCT00252694 Phase 3 candesartan
35 DIabetic Retinopathy Candesartan Trials. Completed NCT00252720 Phase 3 candesartan
36 Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) Completed NCT00542178 Phase 3 Hypoglycemic Agents;Standard glycemia control;Intensive BP treatment;Standard BP control;Fenofibrate;Simvastatin;Placebo
37 Diabetic Retinopathy Study (DRS) Completed NCT00000160 Phase 3
38 Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy Completed NCT01627977 Phase 3
39 Bevacizumab Versus Ranibizumab for Diabetic Retinopathy Completed NCT00545870 Phase 3 bevacizumab;Ranibizumab
40 Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment Completed NCT00417833 Phase 2, Phase 3 Intravitreal Bevacizumab
41 Diabetic Retinopathy Vitrectomy Study (DRVS) Completed NCT00000154 Phase 3
42 Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study Completed NCT00604383 Phase 3 ruboxistaurin;placebo
43 25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China Recruiting NCT02328118 Phase 2, Phase 3 Ranibizumab;Triamcinolone Acetonide
44 25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial Recruiting NCT02447185 Phase 3 Ranibizumab;Triamcinolone Acetonide
45 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR Recruiting NCT02858076 Phase 2, Phase 3 2-mg Intravitreous Aflibercept Injection
46 Anti-VEGF Treatment for Prevention of PDR/DME Recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
47 PROMINENT-Eye Ancillary Study (Protocol AD) Recruiting NCT03345901 Phase 3 Pemafibrate;Placebo
48 DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME Recruiting NCT03321513 Phase 3 intravitreous aflibercept;Bevacizumab + Deferred Aflibercept Group
49 Treatment for CI-DME in Eyes With Very Good VA Study Recruiting NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept
50 The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT Active, not recruiting NCT02157350 Phase 3

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: diabetes complications

Genetic Tests for Microvascular Complications of Diabetes 1

Genetic tests related to Microvascular Complications of Diabetes 1:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 1 28 VEGFA

Anatomical Context for Microvascular Complications of Diabetes 1

MalaCards organs/tissues related to Microvascular Complications of Diabetes 1:

38
Eye, Lung, Brain, Kidney, Heart

Publications for Microvascular Complications of Diabetes 1

Articles related to Microvascular Complications of Diabetes 1:

(show top 50) (show all 616)
# Title Authors Year
1
The expression of the Slit-Robo signal in the retina of diabetic rats and the vitreous or fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. ( 28973045 )
2017
2
MicroRNA-200b Expression in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. ( 28571008 )
2017
3
Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report. ( 28923115 )
2017
4
Association of IL-6 Gene (-174 and -572 G/C) Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Population. ( 28651253 )
2017
5
Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy. ( 27860331 )
2017
6
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. ( 28272234 )
2017
7
Circumpapillary retinal nerve fiber layer thickness, anterior lamina cribrosa depth, and lamina cribrosa thickness in neovascular glaucoma secondary to proliferative diabetic retinopathy: a cross-sectional study. ( 28446148 )
2017
8
A case of pseudoxanthoma elasticum with proliferative diabetic retinopathy. ( 28978321 )
2017
9
Association of Complement C5 Gene Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Han Population. ( 26934706 )
2016
10
Irisin modulates the association of interleukin-17A with the presence of non-proliferative diabetic retinopathy in patients with type 2 diabetes. ( 26940815 )
2016
11
Association between FNDC5 genetic variants and proliferative diabetic retinopathy in a Chinese population. ( 26926664 )
2016
12
Preoperative intravitreal injection of ranibizumab for patients with severe proliferative diabetic retinopathy contributes to a decreased risk of postoperative neovascular glaucoma. ( 27010230 )
2016
13
Tumor necrosis factor-like weak inducer of apoptosis association with proliferative diabetic retinopathy and promotes proliferation and collagen synthesis in retinal ARPE-19 cells. ( 27050952 )
2016
14
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. ( 26039997 )
2015
15
Genetic algorithm based feature selection combined with dual classification for the automated detection of proliferative diabetic retinopathy. ( 25841182 )
2015
16
Social deprivation as a risk factor for late presentation of proliferative diabetic retinopathy. ( 25733801 )
2015
17
Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. ( 25784784 )
2015
18
High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. ( 25822410 )
2015
19
Re: Role of combined cataract surgery and ranibizumab injection in postoperative macula edema in non-proliferative diabetic retinopathy. ( 25635581 )
2015
20
Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to-mesenchymal transition (EndoMT). ( 25637870 )
2015
21
The effects of pleiotrophin in proliferative diabetic retinopathy. ( 25617851 )
2015
22
Role of NF-I_B activation and VEGF gene polymorphisms in VEGF up regulation in non-proliferative and proliferative diabetic retinopathy. ( 25956512 )
2015
23
The rs3917779 polymorphism of P-selectin's significant association with proliferative diabetic retinopathy in Yazd, Iran. ( 26344728 )
2015
24
The -308G>a polymorphism of the TNF gene is associated with proliferative diabetic retinopathy in Caucasian Brazilians with type 2 diabetes. ( 25634985 )
2015
25
Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy. ( 25609907 )
2015
26
Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy. ( 27215012 )
2015
27
Upregulated Expression of Heparanase in the Vitreous of Patients With Proliferative Diabetic Retinopathy Originates From Activated Endothelial Cells and Leukocytes. ( 26720478 )
2015
28
The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. ( 24871583 )
2015
29
Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy. ( 25604687 )
2015
30
Multimodal Characterization of Proliferative Diabetic Retinopathy Reveals Alterations in Outer Retinal Function and Structure. ( 25601533 )
2015
31
Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy. ( 26120271 )
2015
32
Increase of Sialylated N-Glycansin Eyes with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy. ( 26177396 )
2015
33
The tumor necrosis factor superfamily members TWEAK, TNFSF15 and fibroblast growth factor-inducible protein 14 are upregulated in proliferative diabetic retinopathy. ( 25676319 )
2015
34
Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. ( 25631486 )
2015
35
Painless Indirect Argon Laser in High Risk Proliferative Diabetic Retinopathy. ( 25902110 )
2015
36
Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. ( 25686060 )
2015
37
Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis. ( 26321864 )
2015
38
Expression of intraocular peroxisome proliferator-activated receptor gamma in patients with proliferative diabetic retinopathy. ( 25468312 )
2015
39
Indications of lymphatic endothelial differentiation and endothelial progenitor cell activation in the pathology of proliferative diabetic retinopathy. ( 25899460 )
2015
40
CHRONIC MYELOID LEUKEMIA DIAGNOSED IN A PATIENT WITH UNCONTROLLED PROLIFERATIVE DIABETIC RETINOPATHY. ( 25719936 )
2015
41
Identification of chemokines and growth factors in proliferative diabetic retinopathy vitreous. ( 25401103 )
2014
42
Fourier-domain optical coherence tomography evaluation of retinal and optic nerve head neovascularisation in proliferative diabetic retinopathy. ( 24158844 )
2014
43
Pulsatile ocular blood flow changes after panretinal photocoagulation treatment in patients with proliferative diabetic retinopathy. ( 25558661 )
2014
44
Macular tractional retinoschisis in proliferative diabetic retinopathy: clinical characteristics and surgical outcome. ( 24107645 )
2014
45
Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy. ( 25349789 )
2014
46
Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. ( 25329921 )
2014
47
Angiogenic potential of vitreous from proliferative diabetic retinopathy and eales' disease patients. ( 25310689 )
2014
48
Computer aided quantification for retinal lesions in patients with moderate and severe non-proliferative diabetic retinopathy: a retrospective cohort study. ( 25359611 )
2014
49
Chimerin 2 genetic polymorphisms are associated with non-proliferative diabetic retinopathy in Taiwanese type 2 diabetic patients. ( 24854763 )
2014
50
Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy. ( 25371057 )
2014

Variations for Microvascular Complications of Diabetes 1

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 VEGFA NM_001025366.2(VEGFA): c.-94C> G single nucleotide variant risk factor rs2010963 GRCh37 Chromosome 6, 43738350: 43738350

Expression for Microvascular Complications of Diabetes 1

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.

Pathways for Microvascular Complications of Diabetes 1

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CTGF CXCL12 FGF2 FLT1 HGF IGF1
2
Show member pathways
13.81 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
3
Show member pathways
13.73 CTGF CXCL12 FGF2 FLT1 HGF IGF1
4
Show member pathways
13.67 ANGPT2 CCL2 CXCL12 CXCL8 FLT1 HGF
5
Show member pathways
13.45 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
6
Show member pathways
13.4 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
7
Show member pathways
13.38 CCL2 CXCL8 FGF2 HGF ICAM1 MMP9
8
Show member pathways
13.34 CTGF CXCL12 FGF2 FLT1 HGF IGF1
9
Show member pathways
13.28 CTGF CXCL12 FGF2 FLT1 HGF IGF1
10
Show member pathways
13.24 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
11
Show member pathways
13.08 CTGF CXCL12 FGF2 FLT1 HGF IGF1
12
Show member pathways
13.07 FGF2 HGF IGF1 MMP9 TGFB2 VEGFA
13
Show member pathways
12.99 ANGPT2 FGF2 FLT1 HGF IGF1 VEGFA
14
Show member pathways
12.99 CCL2 CTGF CXCL12 FGF2 FLT1 HGF
15 12.83 CXCL12 CXCL8 FGF2 HGF IGF1 MMP9
16 12.79 ANGPT2 FGF2 FLT1 HGF IGF1 TGFB2
17
Show member pathways
12.77 FGF2 ICAM1 MMP9 TGFB2 VCAM1
18
Show member pathways
12.76 ANGPT2 FGF2 FLT1 HGF IGF1 VEGFA
19
Show member pathways
12.74 CTGF CXCL12 FGF2 FLT1 HGF IGF1
20
Show member pathways
12.68 CCL2 CXCL12 ICAM1 MMP9 VCAM1 VEGFA
21
Show member pathways
12.6 ANGPT2 CXCL8 FGF2 ICAM1 MMP9 TGFB2
22
Show member pathways
12.41 CCL2 ICAM1 VCAM1 VEGFA
23 12.35 FGF2 HGF IGF1 MMP9 TGFB2 VEGFA
24 12.28 CXCL8 FLT1 IGF1 MMP9
25
Show member pathways
12.23 CCL2 CXCL12 CXCL8 ICAM1 MMP9 VCAM1
26 12.14 CCL2 ICAM1 MMP9 VCAM1 VEGFA
27 12.11 FGF2 HGF IGF1 VCAM1 VEGFA
28 12.06 CTGF ICAM1 MMP9 VCAM1
29 12.06 CCL2 CXCL8 ICAM1 MMP9
30 12.01 CCL2 ICAM1 MMP9 VCAM1
31
Show member pathways
11.98 CCL2 CXCL12 CXCL8
32 11.96 ANGPT2 FLT1 IGF1 VEGFA
33 11.94 FGF2 IGF1 TGFB2 VCAM1
34 11.93 CXCL12 CXCL8 ICAM1 VCAM1
35 11.88 CCL2 CXCL8 ICAM1 TGFB2 VCAM1 VEGFA
36
Show member pathways
11.82 CXCL12 CXCL8 VCAM1
37 11.8 FGF2 IGF1 VEGFA
38 11.76 CXCL8 MMP9 VEGFA
39 11.76 CCL2 CXCL12 CXCL8 FLT1 ICAM1 TGFB2
40 11.73 FGF2 IGF1 MMP9 TGFB2 VEGFA
41 11.71 ICAM1 TGFB2 VCAM1
42
Show member pathways
11.69 CXCL8 ICAM1 MMP9 VCAM1 VEGFA
43 11.68 CXCL8 IGF1 MMP9
44 11.64 ANGPT2 CCL2 FGF2 FLT1 HGF MMP9
45 11.59 FGF2 HGF IGF1 VEGFA
46 11.57 FGF2 TGFB2 VEGFA
47 11.57 CCL2 CXCL8 ICAM1
48 11.56 CTGF ICAM1 MMP9
49 11.54 CCL2 CXCL8 HGF ICAM1 TGFB2 VCAM1
50 11.51 CXCL8 ICAM1 VCAM1

GO Terms for Microvascular Complications of Diabetes 1

Cellular components related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
2 extracellular matrix GO:0031012 9.56 ICAM1 MMP9 SERPINF1 TGFB2
3 extracellular space GO:0005615 9.53 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
4 platelet alpha granule lumen GO:0031093 9.46 HGF IGF1 TGFB2 VEGFA

Biological processes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.93 CTGF SERPINF1 TGFB2 VEGFA
2 extracellular matrix organization GO:0030198 9.91 FGF2 ICAM1 MMP9 VCAM1
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 CCL2 CTGF FGF2 ICAM1
4 activation of MAPK activity GO:0000187 9.86 FGF2 HGF IGF1
5 positive regulation of cell proliferation GO:0008284 9.86 CTGF CXCL12 FGF2 FLT1 HGF IGF1
6 kidney development GO:0001822 9.85 SERPINF1 TGFB2 VEGFA
7 cellular response to tumor necrosis factor GO:0071356 9.85 CCL2 CXCL8 ICAM1 VCAM1
8 positive regulation of cell migration GO:0030335 9.85 CXCL12 FLT1 HGF IGF1 MMP9 VEGFA
9 negative regulation of angiogenesis GO:0016525 9.84 ANGPT2 SERPINF1 TGFB2
10 platelet degranulation GO:0002576 9.84 HGF IGF1 TGFB2 VEGFA
11 chemotaxis GO:0006935 9.83 CCL2 CXCL12 CXCL8 FGF2 FLT1
12 cellular response to interleukin-1 GO:0071347 9.82 CCL2 CXCL8 ICAM1
13 chemokine-mediated signaling pathway GO:0070098 9.82 CCL2 CXCL12 CXCL8
14 positive regulation of endothelial cell proliferation GO:0001938 9.81 CXCL12 FGF2 VEGFA
15 neutrophil chemotaxis GO:0030593 9.81 CCL2 CXCL8 TGFB2
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 HGF ICAM1 IGF1 VEGFA
17 cell chemotaxis GO:0060326 9.8 CCL2 CXCL12 HGF VCAM1
18 response to hypoxia GO:0001666 9.8 ANGPT2 CXCL12 ICAM1 TGFB2 VCAM1 VEGFA
19 positive regulation of MAP kinase activity GO:0043406 9.79 FGF2 FLT1 VEGFA
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 FLT1 HGF IGF1 TGFB2
21 response to heat GO:0009408 9.77 CXCL12 IGF1 SST
22 positive regulation of cell division GO:0051781 9.76 FGF2 TGFB2 VEGFA
23 animal organ regeneration GO:0031100 9.75 ANGPT2 CXCL12 HGF
24 response to amino acid GO:0043200 9.73 CTGF ICAM1 SST
25 positive chemotaxis GO:0050918 9.71 CXCL12 FGF2 HGF VEGFA
26 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.7 FLT1 VCAM1 VEGFA
27 embryonic digestive tract development GO:0048566 9.69 CXCL8 TGFB2
28 macrophage differentiation GO:0030225 9.69 MMP9 VEGFA
29 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.69 HGF IGF1
30 positive regulation of calcium ion import GO:0090280 9.68 CCL2 CXCL12
31 embryonic morphogenesis GO:0048598 9.68 FGF2 FLT1
32 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.68 FLT1 VEGFA
33 cell migration involved in sprouting angiogenesis GO:0002042 9.67 FGF2 VEGFA
34 PERK-mediated unfolded protein response GO:0036499 9.66 CCL2 CXCL8
35 response to acidic pH GO:0010447 9.65 SERPINF1 SST
36 positive regulation of phospholipase C activity GO:0010863 9.65 FGF2 FLT1
37 induction of positive chemotaxis GO:0050930 9.63 CXCL12 CXCL8 VEGFA
38 positive regulation of angiogenesis GO:0045766 9.63 ANGPT2 CXCL8 FGF2 FLT1 HGF VEGFA
39 positive regulation of axon extension involved in axon guidance GO:0048842 9.62 CXCL12 VEGFA
40 membrane to membrane docking GO:0022614 9.6 ICAM1 VCAM1
41 myoblast proliferation GO:0051450 9.57 HGF IGF1
42 angiogenesis GO:0001525 9.56 ANGPT2 CCL2 CTGF CXCL8 FGF2 FLT1
43 regulation of receptor activity GO:0010469 9.32 CCL2 CTGF CXCL12 CXCL8 FGF2 HGF
44 cell adhesion GO:0007155 10.06 CCL2 CTGF CXCL12 ICAM1 VCAM1

Molecular functions related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.56 CTGF ICAM1 IGF1 VCAM1
2 chemokine activity GO:0008009 9.5 CCL2 CXCL12 CXCL8
3 chemoattractant activity GO:0042056 9.46 CXCL12 FGF2 HGF VEGFA
4 cytokine activity GO:0005125 9.43 CCL2 CXCL12 CXCL8 FGF2 TGFB2 VEGFA
5 growth factor activity GO:0008083 9.17 CTGF CXCL12 FGF2 HGF IGF1 TGFB2

Sources for Microvascular Complications of Diabetes 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....